Klassen Preston
- SEC CIK
- 0001493056
No open-market purchases or sales filed in the past year.
Current role at each company
- RGLS Regulus Therapeutics Inc.President & Head of R & Das of Jun 27, 2025
- MTCR Metacrine, Inc.Directoras of Mar 24, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Klassen Preston as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
RGLS Regulus Therapeutics Inc.
President & Head of R & D2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Klassen PrestonPresident & Head of R & D | PPurchase | +12.0K | $7.99 | +$95.9K | +33.3%48.1K after | |
| Jan 15, 2025 (view filing) | Jan 13 | 2 days | Klassen PrestonPresident & Head of R & D | SSale | −31.4K | $1.26 | −$39.6K | −46.6%36.1K after | 10b5-1 |
MTCR Metacrine, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 27, 2023 (view filing)4:42 PM ET | Jan 26 | 1 day | Klassen PrestonPresident & CEO | SSale | −380.6K | $0.4132 | −$157.3K | −41.3%541.9K after | |
| Apr 20, 2022 (view filing) | Apr 19 | 1 day | Klassen PrestonPresident & CEO | SSale | −44.7K | $0.5003 | −$22.4K | −4.6%922.5K after | 2 lots |